Basic Information
| LncRNA/CircRNA Name | HOXD-AS1 |
| Synonyms | HAGLR, HOXD-AS1, Mdgt |
| Region | GRCh38_2:176164051-176188958 |
| Ensemble | ENSG00000224189 |
| Refseq | NR_033979 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Luciferase reporter assay, Western blot, RIP |
| Sample | gastric cancer tissues and cell lines(GES-1,BGC823,SGC7901) |
| Expression Pattern | up-regulated |
| Function Description | Our results revealed that HOXD-AS1 was upregulated in DDP-resistant gastric cancer tissues and cells. Patients with gastric cancer with high HOXD-AS1 expression levels had a poor prognosis. |
| Pubmed ID | 31551012 |
| Year | 2019 |
| Title | HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2. |
External Links
| Links for HOXD-AS1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |